Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 16.0

Eligibility Criteria:
Key Inclusion Criteria:~* Chronic genotype 1-4 HCV infection~* For Cohorts 1-9, HCV RNA ≥ 100,000 IU/mL at screening (no HCV RNA restriction for Cohort 10)~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Key Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Presence of cirrhosis~* Prior exposure to approved or experimental HCV Protease Inhibitors~* Co-infection with HIV or hepatitis B virus (HBV)~* Current or prior history of clinical hepatic decompensation~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with participant's treatment, assessment or compliance with the protocol~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (GT 1a, Cohort 1) (Type: PLACEBO_COMPARATOR): Participants with genotype (GT) 1a HCV infection will receive placebo once daily for 3 days under fasted conditions.
- Voxilaprevir 50 mg (GT 1a, Cohort 1) (Type: EXPERIMENTAL): Participants with GT 1a HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
- Voxilaprevir 100 mg (GT 1a, Cohort 1) (Type: EXPERIMENTAL): Participants with GT 1a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
- Voxilaprevir 300 mg (GT 1a, Cohort 1) (Type: EXPERIMENTAL): Participants with GT 1a HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
- Placebo (GT 3, Cohort 2) (Type: PLACEBO_COMPARATOR): Participants with GT 3 HCV infection will receive placebo once daily for 3 days under fasted conditions.
- Voxilaprevir 50 mg (GT 3, Cohort 2) (Type: EXPERIMENTAL): Participants with GT 3 HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
- Voxilaprevir 100 mg (GT 3, Cohort 2) (Type: EXPERIMENTAL): Participants with GT 3 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
- Voxilaprevir 300 mg (GT 3, Cohort 2) (Type: EXPERIMENTAL): Participants with GT 3 HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
- Placebo (GT 2, Cohort 3) (Type: PLACEBO_COMPARATOR): Participants with GT 2 HCV infection will receive placebo once daily for 3 days under fasted conditions.
- Voxilaprevir 100 mg (GT 2, Cohort 3) (Type: EXPERIMENTAL): Participants with GT 2 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
- Voxilaprevir 100 mg (GT 4, Cohort 4) (Type: EXPERIMENTAL): Participants with GT 4 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
- Voxilaprevir 100 mg (GT 1b, Cohort 5) (Type: EXPERIMENTAL): Participants with GT 1b HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
- Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) (Type: EXPERIMENTAL): Participants with GT 3a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fed conditions.
- Voxilaprevir 600 mg (Cohorts 7-9) (Type: EXPERIMENTAL): Participants with genotypes 1a, 1b, 2, 3, or 4 HCV infection will receive voxilaprevir up to 600 mg under fasted or fed conditions for 3 days.
- Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 1, Cohort 10) (Type: EXPERIMENTAL): Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 after moderate fat meal and voxilaprevir 100 mg plus sofosbuvir (SOF)/velpatasvir (VEL) (400/100 mg) fixed-dose combination (FDC)on Days 2 and 3 after either a light or moderate-fat meal.
- Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 2, Cohort 10) (Type: EXPERIMENTAL): Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 and voxilaprevir 100 mg plus SOF/VEL (400/100 mg) FDC on Days 2 and 3 after moderate fat meal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete